安科生物(300009.SZ):擬推第4期員工持股計劃
格隆匯7月10日丨安科生物(300009.SZ)公佈第4期員工持股計劃,本持股計劃受讓的股份總數不超過289.4406萬股,佔公司目前股份總數1,672,521,258股的0.17%,擬籌集資金總額不超過1,267.75萬元,具體金額根據員工實際繳款金額確定,資金來源為公司員工合法薪酬、自籌資金和法律、行政法規允許的其他方式。本持股計劃參與對象為公司腫瘤事業部團隊中發揮關鍵作用的管理人員及核心骨幹,總人數不超過37人,不包括公司董事、監事及高級管理人員,也不涉及公司實際控制人、控股股東、持有公司股份5%以上的股東及其近親屬,具體參與對象以本持股計劃實際執行情況為準。董事會可以根據認購款繳納情況、員工變動情況對本持股計劃的員工名單、分配比例進行調整。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.